Read, Watch or Listen

Experimental peptides have become darlings among longevity influencers, chiropractors and doctors, yet the Food and Drug Administration has not approved them for safety or effectiveness. On Oct. fourteenth, a temporary “access policy” appeared on a White House docket, proposing that licensed pharmacies could manufacture and sell certain unapproved peptides to consumers. Scientists at the FDA warned in a July meeting that these drugs had not undergone adequate clinical trials. A panel that advises the FDA disagreed, voting to loosen restrictions; many new appointees hold financial stakes in the peptide industry. The debate highlights tension between medical freedom and patient safety, underscoring the need for reliable information in a market driven by hype. Consumers must rely on accurate data, but much of the hype around peptides is misleading. KFF Health News flags four misleading phrases commonly used by promoters and one truth. Peptides are not drugs unless used to treat, prevent

By Claire D. | JQJO News